• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an mA dependent manner.

作者信息

Han Yongzheng, Li Chengming, Wu Guangzhen

机构信息

Department of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.

出版信息

Int J Biol Sci. 2025 Aug 16;21(12):5284-5286. doi: 10.7150/ijbs.120024. eCollection 2025.

DOI:10.7150/ijbs.120024
PMID:40959282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12435217/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12435217/1d4e6e8cf5b7/ijbsv21p5284g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12435217/1d4e6e8cf5b7/ijbsv21p5284g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12435217/1d4e6e8cf5b7/ijbsv21p5284g001.jpg

相似文献

1
Comment on IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an mA dependent manner.评论：胰岛素样生长因子2 mRNA结合蛋白3通过以N6-甲基腺苷依赖的方式增强细胞周期蛋白依赖性激酶6的mRNA稳定性，促进膀胱癌的增殖和顺铂耐药性。
Int J Biol Sci. 2025 Aug 16;21(12):5284-5286. doi: 10.7150/ijbs.120024. eCollection 2025.
2
IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner.IGF2BP3通过以m6A依赖的方式增强CDK6的mRNA稳定性来促进膀胱癌的增殖和顺铂耐药性。
Int J Biol Sci. 2025 Feb 18;21(5):2048-2066. doi: 10.7150/ijbs.103522. eCollection 2025.
3
IGF2BP3/NCBP1 complex inhibits renal tubular senescence through regulation of CDK6 mRNA stability.IGF2BP3/NCBP1 复合物通过调节 CDK6 mRNA 的稳定性抑制肾小管衰老。
Transl Res. 2024 Nov;273:1-15. doi: 10.1016/j.trsl.2024.06.004. Epub 2024 Jun 28.
4
The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression.N6-甲基腺苷阅读器IGF2BP3通过增强HSP90AB1的表达促进膀胱癌进展。
FEBS J. 2025 Jul;292(13):3477-3493. doi: 10.1111/febs.70068. Epub 2025 Mar 19.
5
Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.多组学分析揭示了 IGF2BP3/SPHK1 信号在肌层浸润性膀胱癌肿瘤干细胞中对预后和免疫治疗反应的预测价值。
J Transl Med. 2024 Oct 4;22(1):900. doi: 10.1186/s12967-024-05685-8.
6
IGF2BP3 promotes autophagy-mediated TNBC metastasis via m6A-dependent, cap-independent c-Met translation.胰岛素样生长因子2 mRNA结合蛋白3通过m6A依赖的、不依赖帽结构的c-Met翻译促进自噬介导的三阴性乳腺癌转移。
Cell Commun Signal. 2025 Jul 1;23(1):303. doi: 10.1186/s12964-025-02316-7.
7
O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene via mA modification.O-连接的N-乙酰葡糖胺化的YTHDF2通过m⁶A修饰调控肿瘤抑制基因，从而促进膀胱癌进展。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025 May 28;50(5):827-839. doi: 10.11817/j.issn.1672-7347.2025.250202.
8
hsa_circ_0007376 Promotes Gastric Cancer Proliferation and Malignant Metastasis by Enhancing the Stability of IGF2BP3.
Turk J Gastroenterol. 2025 May 20. doi: 10.5152/tjg.2025.24491.
9
Dual regulation of FZD1/7 by IGF2BP3 enhances stem-like properties and carboplatin resistance in triple-negative breast cancer.IGF2BP3对FZD1/7的双重调控增强了三阴性乳腺癌的干细胞样特性和对卡铂的耐药性。
Cancer Lett. 2025 Jul 22;632:217944. doi: 10.1016/j.canlet.2025.217944.
10
Epigenetic mechanism of RBM15 in affecting cisplatin resistance in laryngeal carcinoma cells by regulating ferroptosis.RBM15 通过调控铁死亡影响喉癌细胞顺铂耐药的表观遗传机制。
Biol Direct. 2024 Jul 23;19(1):57. doi: 10.1186/s13062-024-00499-6.

本文引用的文献

1
IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner.IGF2BP3通过以m6A依赖的方式增强CDK6的mRNA稳定性来促进膀胱癌的增殖和顺铂耐药性。
Int J Biol Sci. 2025 Feb 18;21(5):2048-2066. doi: 10.7150/ijbs.103522. eCollection 2025.
2
Hsa_circ_0005320 affects cell proliferation and the cell cycle via the IGF2BP3/CDK2 axis in bladder cancer.Hsa_circ_0005320 通过 IGF2BP3/CDK2 轴影响膀胱癌中的细胞增殖和细胞周期。
Cell Signal. 2024 Jul;119:111154. doi: 10.1016/j.cellsig.2024.111154. Epub 2024 Mar 31.
3
IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
IGF2BP3 可防止膀胱癌和发育过程中 HMGB1 mRNA 的降解。
Cell Mol Biol Lett. 2024 Mar 19;29(1):39. doi: 10.1186/s11658-024-00545-1.
4
Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy.乳糖酰化驱动的 FTO 靶向 CDK2 加重糖尿病性视网膜病变中的微血管异常。
EMBO Mol Med. 2024 Feb;16(2):294-318. doi: 10.1038/s44321-024-00025-1. Epub 2024 Jan 31.
5
Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma.通过针对恶性神经胶质瘤中 IGF2BP3 诱导的 NETosis 来克服溶瘤单纯疱疹病毒治疗的耐药性。
Nat Commun. 2024 Jan 2;15(1):131. doi: 10.1038/s41467-023-44576-2.
6
FTO promotes proliferation and migration of bladder cancer via enhancing stability of STAT3 mRNA in an m6A-dependent manner.FTO 通过依赖 m6A 的方式促进膀胱癌的增殖和迁移，增强 STAT3 mRNA 的稳定性。
Epigenetics. 2023 Dec;18(1):2242688. doi: 10.1080/15592294.2023.2242688.
7
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N-methyladenosine modification of PD-L1 mRNA in breast cancer.METTL3/IGF2BP3 轴通过上调乳腺癌中 PD-L1 mRNA 的 N6-甲基腺苷修饰来抑制肿瘤免疫监视。
Mol Cancer. 2022 Feb 23;21(1):60. doi: 10.1186/s12943-021-01447-y.
8
FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner.FTO通过FTO/miR-576/CDK6轴以m6A依赖的方式促进膀胱癌的肿瘤增殖。
Cell Death Discov. 2021 Nov 1;7(1):329. doi: 10.1038/s41420-021-00724-5.
9
FTO modifies the m6A level of MALAT and promotes bladder cancer progression.FTO 修饰 MALAT 的 m6A 水平并促进膀胱癌进展。
Clin Transl Med. 2021 Feb;11(2):e310. doi: 10.1002/ctm2.310.
10
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.哌柏西利联合来曲唑与来曲唑单药一线治疗雌激素受体阳性、HER2 阴性、晚期乳腺癌（PALOMA-1/TRIO-18）的随机 2 期研究。
Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.